Evidence map›Paper›PMID 41419859›Full record

ArticleBMC medical genomics2025

Construction and verification of a prognostic model for prostate cancer based on ribosome biogenesis-related genes.

JiaWei Xie, YanHong Tang, YuHang Wang, Xin Gao, FaJun Fu, YuMing Liu, Chen Yi, Gang Zhou, ZiJian Wang, Can Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

JiaWei Xie *The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
YanHong Tang *Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Hunan Normal University, Changsha, 410000, China.
YuHang WangDepartment of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China.
Xin GaoDepartment of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, Hunan, 410008, China.
FaJun FuThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
YuMing LiuThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
Chen YiThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
Gang ZhouThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
ZiJian WangThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
Can ChenThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
PeiMin JinThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China.
Yi CaiDepartment of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China. cai-yi@csu.edu.cn.
JianJun ZhouThe Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410008, China. zjj1228@163.com.

Funding

Natural Science Foundation of Changsha City, Hunan Province, China kq2502328Natural Science Foundation of Hunan Province, China 2025JJ60615Natural Science Foundation of Hunan Province, China 2025JJ80579
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is a prevalent and often aggressive malignancy. While ribosome production is a critical process in numerous cancers, the role of ribosome biogenesis-related genes (RB-RGs) in PCa remains underexplored. Therefore, this study aims to examine the expression characteristics of RB-RGs as potential prognostic markers in PCa.

methodsTranscriptomic data were obtained from public databases to pinpoint differentially expressed genes (DEGs) associated with PCa. Among these, DEGs that were also identified as regulatory genes were selected as candidate genes and subjected to regression analysis to determine those with prognostic significance. A prognostic risk model was then created and subjected to validation. A standalone prognostic evaluation was performed. Additionally, analyses for enrichment, immune infiltration, and drug prediction were conducted for both high- and low-risk PCa cohorts. Finally, the levels of the prognostic genes were validated through reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western Blot (WB).

resultsSMARCA4, FBLL1, RRS1, and NVL were selected as prognostic genes. A risk model, exhibited considerable precision in evaluating the risk of PCa. The risk score, in conjunction with the prostate-specific antigen (PSA) score and Gleason score, has been recognized as independent prognostic factors for PCa. Analysis of biological pathways indicated notable variations in pathways, especially the cell cycle, when comparing the high- and low-risk groups. The expression of prognostic genes demonstrated a correlation with the presence of 21 distinct types of immune cells, notably including type-17 T helper cells, within PCa samples. Furthermore, notable variations in the levels of target genes (AKT1, CDK1, HIF1A, NFKB1, SRC, and TRIM24) were detected between the high- and low-risk cohorts in relation to different chemotherapeutic agents. PCR analysis showed that NVL and SMARCA4 were significantly upregulated in PCa samples (p < 0.05), with no significant difference in RRS 1. WB analysis showed that SMARCA4, FBLL 1, and RRS1 and NVL were differently expressed in both PCa and Control, with higher upregulation in PCa than in the control group.

conclusionAmong RB-RGs, SMARCA4, FBLL1, RRS1 and NVL were identified as prognostic genes for PCa, thereby providing a new direction for clinical disease treatment.

Indexed as

Biomarkers, TumorProstatic NeoplasmsRibosomesDNA HelicasesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleNuclear ProteinsPrognosisTranscription FactorsBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription FactorsIndependent prognostic factorsPrognostic genesProstate cancerRibosome biogenesis-related genes

Identifiers

PMID41419859
PMCPMC12717746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.